How a hormone signal changes the blood
Red blood cells carry oxygen, and the body adjusts their supply partly through the kidneys. When oxygen delivery seems low, the kidneys release erythropoietin, a hormone that tells bone marrow to make more red cells. Testosterone can shift this system toward greater production: it can increase the marrow’s response to erythropoietin and alter signals that regulate iron, a key ingredient in new red cells.
The result may be a higher red-cell concentration, called hematocrit—the share of blood volume occupied by red cells. When that rise is substantial, the condition is known as secondary polycythemia: “secondary” means it is driven by an outside cause, such as a medication, rather than a primary disorder of the marrow.
Why the change matters—and how it is found
More red cells can improve oxygen-carrying capacity, but they also make blood more concentrated and harder to move through small vessels. A high hematocrit is therefore a reason for medical attention, especially because it can contribute to circulation problems and may raise the risk of complications. The degree of risk depends on the person and the extent of the increase; it is not possible to judge from symptoms alone.
A routine blood test can reveal the change before it is obvious. Clinicians can track hematocrit over time and weigh the result alongside the testosterone dose, treatment benefits, and other health factors. If the count climbs too high, they may adjust the treatment or investigate other causes. That makes monitoring part of the therapy itself: it helps catch a gradual shift in blood composition before it becomes a larger problem.
